


cancer executives Connecting All Oncology Leaders



Delivering Cancer Care in the COVID-19 Era Session 3: Imperatives for Oncology Success

Association of Cancer Executives Webinar June 24, 2020





About ACE

Association of Cancer Executives (ACE) is a national organization committed to the leadership development of oncology executives through continuing education and professional networking designed to promote improvement in patient care delivery.



association of

Connecting All Oncology Leaders

ACE Membership

Become a part of the premier association for oncology administration. ACE members represent a wide range of leading oncology institutions nationwide.

Join ACE for only \$275 per year!

Please visit <u>www.cancerexecutives.org</u> for more information.





We look forward to welcoming you to Rancho Mirage, CA January 31 – February 2, 2021!

Sponsorship and exhibitor opportunities are now available!

Attendee registration will open later this year

Please visit <u>www.cancerexecutivesmeeting.com</u> for more information.



association of cancer executives

Connecting All Oncology Leaders





A special monthly webinar series for ACE Members: **Delivering Cancer Care in the Covid-19 Era** Session 3: Imperatives for Health System Success: An Oncology Lens Wednesday, June 24th | 1:00PM EDT



Nancy Bookbinder Webinar Moderator



Sophie Clamon *Practice Manager* Chartis Oncology Solutions



Ryan Langdale, MBA *Principal* The Chartis Group



Kelley D. Simpson, MBA Director The Chartis Group

Delivering Cancer Care in the COVID-19 Era

Imperatives for Oncology Success







Imperative 1: Reactive and Recapture the Patient


Imperatives: Reactivate & Recapture your Patient

Key Take-Aways

Reactivation			Market Positioning	Care Model	
Key Observation		Implications			
•	Cancer care was profoundly disrupted in March-May, in highly localized fashion	1. 2. 3.	Volumes of screening, diagnostics and c Access disparities aggravated existing d Threats of re-surge make COVID a "new	isparities in care	
•	Reactivating cancer care is a mission and financial imperative for programs	1. 2.	Reactivation should begin with the scree critical to the pipeline for all other cance The human and financial costs of furthe	er services	
•	Cancer programs must take ownership of the reactivation response given the diffuse "ownership" of screening and surveillance	1. 2. 3.	Coordination will be critical – and oncol Market needs reminder that screening/s Cancer program should lead in process environments to the market	surveillance are routine for a reason	

Key Context: Disruption


Volumes of screening, diagnostics and cancer surgery reduced significantly



Key Context: Disparity

Cancer's existing disparities are being compounded by COVID-19

At its pre-COVID baseline, cancer care was characterized by enormous socio-economic and racial outcome disparity



5-7% of clinical trial representation

COVID has exploited existing health care disparities, with mortality rates in some locations 2X higher for black patients than white

Source: Scott LC, Barker. Pop. Health to Evaluate the Environ. Burden of Cancer at County Level. Prev Chronic Dis 2019;16:180530

Mortality Rate (per 100K)


Black

Key Context: Delay

The COVID experience will likely be our new normal for the foreseeable future

National Context, Local Implications

- Cancer diagnostics and surgery were significantly disrupted in March/April for COVID-19 surge readiness
- While local cases may have "peaked" in some markets, others continue to set new highs and many expect resurges / prolonged exposure to COVID-19
- "New normal" will require careful navigation for cancer demographic – older, immuno-compromised, high/medium acuity (2-3x likelihood of mortality from COVID-19 infection)



Key Context: Impact of Delay

The human and financial costs of delaying cancer care will be profound

According to the American Cancer Society Cancer Action Network:

50% OF PATIENTS

experienced delays in their care due to COVID-19 pandemic

Impacts: upstaging, disease progression, dose reductions,


Source: ACS CAN survey COVID-19 Pandemic Early Effects on Cancer Patients and Survivors: April 2020

10,000

ADDITIONAL DEATHS

expected from diagnostic and care delays in breast and colorectal cancer by 2030

Modeled cumulative excess deaths from colorectal and breast cancers, 2020 to 2030*



Source: Sharpless, N. "COVID-19 and cancer." Science 19 Jun 2020:

Many cancer programs experienced

30-50% REVENUE CONTRACTION

from cancer surgery and diagnostic delays, and further postponement may further erode the standard contribution of the oncology service line:

- \$15-20K contribution margin per NCC
- 25-40% of health system margin


Source: Collateral damage: the impact on outcomes from cancer surgery of the COVID-19 pandemic; Annals of Oncology May 19, 2020

Time is of the essence in retooling care processes to encourage patient presentation, allaying fears, and ensuring screening, diagnostics and surgery are not canceled wholesale in new surges of COVID

Reactivate: Prioritize Patient Population


Reactivation begins with the screening and surveillance cohorts – critical pipeline to all other cancer services

A. Screening & Long-Term Surveillance	B. Recent Survivorship	C. Active Treatment	
 Patients with perceived low-risk (e.g., screening or long term survivorship) who avoid any in- person health care environment 	 Large population of established, post- treatment cancer patients being routinely surveilled, imaged, seen for follow-up 	 Patients with a suspicious finding, ongoing diagnostic work-up, or active cancer treatment plan 	
Avoid care due to significant financial or safety concerns	 Hesitant to return to in-person care; may seek virtual modalities 	 Generally eager to return to care/ seek resolution to cancer 	



Reactivate: Instill Urgency & Lead with Safety

Remind the market that screening and surveillance are routine for a reason, and its safe to visit your environment







Imperative 2: Redirect your Market Strategy


Imperatives: Redirect your Market Strategy

Key Take-Aways

Key Observation Implications 1. The industry continues to feel the effects of new entrants, technology/ digital revolution, and an ever-changing policy landscape 2. Constitutive interval
revolution, and an ever-changing policy landscape
 COVID accelerated trends that were already reshaping the oncology industry Consolidation in oncology practices has been a persistent force, and further consolidation is inevitable as screening/surgical delays cascade through cance sequential value chain to chemo/RT
 Programs have traditionally planned around consumer preference for expertis facilities but we may see a mind shift – placing premium on risk avoidance, convenience, and personalized cancer care
 Post-COVID market dynamics require a 1. Systems' financial health and market landscape changes need to be understoc – and whether they necessitate an offensive or defensive posture
reassessment of legacy market strategies 2. New threats of disruption abound and need to be studied/ mitigated
3. Fundamental assumptions about how/ where care will be delivered need to be challenged and contextualized relative to current investment plans

Redirect: Assess the Market

COVID has introduced new market pressures and demands a reassessment of legacy strategy



Legacy model characterized by....

- Constructed around hospital assets and capital
- Predicated on physical distribution model and sequentially discrete cancer value chain
- Focused on horizontal integration

Emerging model characterized by....

- Constructed around end-user experience
- Disrupted by new competitors, suppliers
- Connected digital/physical cancer environments
- Disintermediation of traditional value chain


+ COVID-19

- Rapid shift in financial health of providers
- Demand for non-traditional environments
- Vast virtual health adoption
- Uneven impact –offense vs. defense

Redirect: Pursue Partnerships

Consolidation has been a persistent force in the market – driven by simple economic forces

Horizontal integration has remade the med onc delivery landscape: >1,300 practices acquired or closed since 2010



The alignment activity in oncology has been the byproduct of simple market forces centered around drug buy

Drug Demand

- Growth market for MO and its logarithmically-increasing buyand-bill drug prices
- Attractive to scale players (One Oncology), distributors (USON), PPS-exempt and DSH hospitals



- Cancer market is crowded and providers pursuing competitive advantage via integration
- Oncologists are fundamental to integrated cancer care



- HOPD commercial rate advantage and 340B discounts of 20-30%
- \$1.0-2.0M of incremental margin per FTE onc in HOPD/340B setting

Labor Supply

- Shortage of >2,200 oncologists (20% demand gap) by 2025
- Scarcity compelling programs to build integrated cancer care through practice acquisitions

Redirect: Pursue Partnerships

Further consolidation inevitable as screening/surgical delays cascade through cancer's sequential value chain

The Struggle is Real

Flatiron Health's report of 270 oncology practices:

- 40% drop in new pt. visits between Feb-Apr.
- 2X cancellations and no-shows
- Chemo cancellations modest at 3-17%...but infusions a trailing indicator

"There's a lot of financial concern that's out there right now about being able to stay open and keep the lights on."

Dr. Bobby Green, Flatiron CMO

Options for Struggling Oncology Practices

Increasing Likeliness

Restructuring


Private Equity and Corporate

> Hospital Alignment

- Service rationalization and clinic or infusion site closures
- Likely limited to smaller or solo-practice groups, oncologists approaching retirement, or practices in rural settings without viable partner channels
- While there has been a flurry of recent PE-acquisitions, deals were likely already in advanced stage before COVID started (e.g., OneOncology, 21st Century)
- PE firms have also been impacted financially and it is unclear how turbulence will impact valuation multiples or the appetite of private equity in the near term
- Most likely path for oncology practices, assuming health systems able to dedicate resources and bandwidth in midst of recovery
- Oncology acquisitions have short timeline to margin accretion, hence the business imperative to move quickly is strong relative to other opportunities
- Systems with strong pre-COVID-19 balance sheets will be best positioned to take advantage


Redirect: Measure Mindshift

Cancer programs have traditionally planned around consumer preference for expertise and destination facilities



Redirect: Measure Mindshift


We need to prepare for mind shift – including a premium placed on risk avoidance, convenience, and personalization



Redirect: Assess the Market

As a cancer executive, what is your cancer program strategic posture?

New Ecosystem



How will COVID influence your cancer program's market strategy?

New Strategic Questions

Are we offensively or defensively postured?

- Offense where do we capitalize on market changes to drive growth and margin accretion in cancer care?
- *Defense* how do we protect programs/ services from better capitalized competitors/ corporate players

Are there new threats of disruption?

- What role will our payers, large corporations and PE firms play in the post-COVID marketplace?
- Are there new partnerships we should be considering to mitigate the risks of disruption?

How/ where will we deliver care?

- Do we need to rethink our delivery network, physical assets, and capital investment plans for cancer care?
- What is our investment roadmap for oncology digital health and is it sufficient to meet the recent quantum leap in adoption?





Imperative 3: Reimagine your Care Model

Imperatives: Reimagine your Care Model

Key Take-Aways

Reactivation	Market Positioning	Care Model	
Key Observation	Implications		
 Oncology programs are being asked to seek margin improvement, demonstrate financial stewardship, and contribute to broader enterprise financial recovery 		re improving clinical resource efficiency s and rationalizing non-revenue producing v steps to close margin gap	
 COVID-induced explosion of telehealth will have a lasting impact on the care model 	given cost efficiencies and patient co 2. Digital impacts on the care model ar	its "peak", we expect adoption to endure onvenience e significant and will need to be factored will potentially alter competitive landscape	
 As with all paradigm shifts – the winners in cancer care will be those innovating and seeking to disrupt themselves 	safety for on-treatment patients	e to COVID in alterative care delivery e team connectivity, and environmental forward thinking providers to differentiate	

Reimagine: Optimize the Model

While generally a profit center – oncology will need to demonstrate financial stewardship as systems recover

IMPROVE RESOURCE EFFICENCY

- Right size department-specific workforce in infusion, radiation, clinics, supportive care
- Optimize APP role and working to top of licensure
- Reassess physician compensation models to align with programmatic goals
- Lean into virtual encounter integration and schedule/template redesign
- Rationalize sites of care

REVIEW YOUR FRONT/BACK OFFICE

- Evaluate charge master, charge capture, drug costs, billing/collections for revenue recapture opportunities and cost out
- Assess automation/self-service to streamline front-end processes and reduce overhead

RATIONALIZE NON-REVENUE PRODUCING PROGRAMS

<u></u>	<u>0</u> _	<u>0</u>
[,[]		

- Set clear KPIs for all non-revenue producing services with clear line of influence to the clinical enterprise – e.g., patient navigation, social work, financial counseling, supportive care
- Evaluate virtual alternatives/ contract solutions in certain services e.g., genetic counseling, tumor registry, patient education

Drive higher margin, high value cancer care

Contribute to enterprise financial recovery

Reimagine: Digital Health

Telehealth is here to stay and must be considered in care model redesign

COVID-19 brought and explosion in telehealth. While usage may have peaked, we expect it to settle well above the its starting point.


% Telehealth for Hematology/Oncology Nationally by week, 2020



Source: The Chartis Group and Kythera Labs Telehealth Adoption Tracker

This requires incorporating telehealth as a critical component of care model and strategic planning.







Change in facilities, staffing and equipment demand as in person visits move to virtual



Process redesign for appointment scheduling, preparation, check in and communications



Disruption to the traditional competitive landscape, potentially reducing geographic barriers to entry

Reimagine: Embrace Innovation

COVID has brought a wave of innovation to maintain access and patient experience while enhancing safety.



- Drive-thru port flushes and injections – e.g., Neulasta Spectrum, Grand Rapids¹
- In-home hydration, injection, and chemo infusion for patient subsets (300% increase in March) University of Pennsylvania²

¹ Mlive Spectrum Health <u>link</u>

 $^{\rm 2}$ "Home Based Chemo Skyrockets at One U.S. Center." Medscape Online. ${\rm link}$

GROWING TELEHEALTH



- Platforms like CancerIQ to extend tele-genetics for virtual genetic counseling *Dignity Health, San Fran.*¹
- Remote clinical trials virtual consults, direct home drug shipping and offsite evaluation² UM Masonic Cancer Center

¹ Advisory Board Oncology Roundtable <u>link</u> ² IQVIA Article <u>link</u> ³ ACCC Webinar <u>link</u>





- COVID testing, in-home swabbing (Ready Respond) Ochsner, New Orleans¹
- Machine learning (e.g. LeanTaas) for infusion scheduling/spacing²
- Virtual waiting room Banner Health, Arizona³

¹ Louisiana Weekly <u>link</u> ² LeanTaas iQueue <u>link</u> 3 Banner Health virtual waiting room <u>link</u>

T. MULTI-MODAL CONNECTIVITY



- iPads and FaceTime video chat in exam room if visitors limited; MDACC¹
- Symptom management apps to track on-treatment well being and assess COVID infection risk OU Stephenson Cancer Center²
- Virtual patient navigation³

¹ MD Anderson Cancer Center <u>link</u>
 ² University of Oklahoma Health Center <u>link</u>
 ³ Association of Oncology Nurse Navigators <u>link</u>

Reimagine: In-Home Cancer Care

Renewed interest in in-home chemotherapy infusions

COVID has created the perfect environment to reconsider the site of care for chemotherapy infusion. Pilot models are underway and CMS is actively removing the legal/regulatory barriers to in-home delivery models.



CARE CONTINUITY

Use in-home care to limit immune suppressed patients exposure to COVID-19 and increase confidence / compliance with care plans that avoid healthcare settings.



PATIENT EXPERIENCE

Patients report enhanced well-being through the reduced travel, improved symptom management and higher adherence to chemotherapy schedules.¹



REGULATORY CHANGE

CMS is making regulatory and reimbursement changes that enable the expansion of home infusion.



https://www.ncbi.nlm.nih.gov/pubmed/21384139

https://www.medscape.com/viewarticle/928505



CAPACITY CONSTRAINTS

Shortage of infusion capacity is driving interest in a model that offloads select patient types to the home-based setting

INTERNATIONAL SUCCESS

Adoption in sophisticated healthcare markets like the UK and Australia and isolated pilots in the U.S. demonstrate the hurdles of patient safety and economics can be overcome.

FINANCIAL VIABILITY

The economics are complex, but with evidence in-home chemo infusions can be safely delivered at half the cost², payor pressure to review care settings is likely to mount.

U.S. CASE STUDY³

UPenn piloted a homebased chemotherapy program when COVID-19 arrived. In a 4-week period from March to April 2020:


- **Referrals rose 300%** from 40 to 135
- **Expanded** the list of chemotherapy agents delivered from 2 to 7
- **Outstanding patient** feedback received, with pilot expansion planned





Summary: Delivering Cancer Care in the COVID-19 Era

Imperatives for Oncology Success



Questions?

Please reach out to one of our colleagues at Chartis Oncology Solutions with any questions about today's content. Thank you for your

time and attention!



Kelley D. Simpson, MBA Director/ Practice Lead Chartis Oncology Solutions

- ksimpson@chartis.com
- (404) 277 6567

Ryan Langdale, MBA

Principal Chartis Oncology Solutions

Sophie Clamon *Practice Manager Chartis Oncology Solutions*

- rlangdale@chartis.com
- (404) 449 3730

sclamon@chartis.com

(865) 804 2836